UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Ubiquitin-conjugating enzyme E2S (UBE2S), a family of E2 protein in the ubiquitination process, is involved in development of various cancers. However, its role in lung adenocarcinoma, has not been well elucidated. In this report, we attempted to investigate expression and function of UBE2S in lung adenocarcinoma. Up-regulation of UBE2S at mRNA, and protein level, was observed in human cancer tissues and lung adenocarcinoma cells. Higher UBE2S expression correlated with poorer prognosis of lung adenocarcinoma patients. UBE2S expression was efficiently suppressed by lentivirus-mediated shRNA strategy in A549 cells, and UBE2S silencing led to reduced cell proliferation, colony formation, and enhanced apoptosis. Inverse results were observed, in UBE2S over-expressed H1299 cells. Microarray analysis indicated that a large number of genes were regulated by UBE2S, and p53 signaling pathway may be critical, to the role of UBE2S in cancer development. Together, UBE2S could be a potential target for lung adenocarcinoma.
Abstract
Ubiquitin-conjugating enzyme E2S (UBE2S), a family of E2 protein in the ubiquitination process, is involved in development of various cancers. However, its role in lung adenocarcinoma, has not been well elucidated. In this report, we attempted to investigate expression and function of UBE2S in lung adenocarcinoma. Up-regulation of UBE2S at mRNA, and protein level, was observed in human cancer tissues and lung adenocarcinoma cells. Higher UBE2S expression correlated with poorer prognosis of lung adenocarcinoma patients. UBE2S expression was efficiently suppressed by lentivirus-mediated shRNA strategy in A549 cells, and UBE2S silencing led to reduced cell proliferation, colony formation, and enhanced apoptosis. Inverse results were observed, in UBE2S over-expressed H1299 cells. Microarray analysis indicated that a large number of genes were regulated by UBE2S, and p53 signaling pathway may be critical, to the role of UBE2S in cancer development. Together, UBE2S could be a potential target for lung adenocarcinoma.
참고문헌 (30)
- Jemal A, "Cancer statistics, 2002", CA Cancer J Clin, 52, pp.23~47 (2002)
- Imielinski M, "Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing", Cell, 150, pp.1107~1120 (2012)
- World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, "McGuire S", WHO Press, 418~419 (2015)
- Alberg AJ, "Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines", Chest, 143, pp.e1S~e29S (2013)
- Paul A, "RNF8- and Ube2S-Dependent Ubiquitin Lysine 11-Linkage Modification in Response to DNA Damage", Mol Cell, 66, pp.458~472e455 (2017)
- Wu T, "UBE2S drives elongation of K11-linked ubiquitin chains by the anaphase-promoting complex", Proc Natl Acad Sci U S A, 107 (2010)
- Garnett MJ, "UBE2S elongates ubiquitin chains on APC", C substrates to promote mitotic exit, 2009, pp.11, 1363~1369
- Bremm A, "Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne", Nat Struct Mol Biol, 17, pp.939~947 (2010)
- Penas C, "The APC", C Ubiquitin Ligase: From Cell Biology to Tumorigenesis, 2011, pp.1, 60~
- Chen MF, "The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma", J Mol Med (Berl), 87, pp.307~320 (2009)
- Roos FC, "Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma", Am J Pathol, 178, pp.853~860 (2011)
- Liang J, "The ubiquitinconjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth", Oncol Rep, 28, pp.1519~1525 (2012)
- Ayesha AK, "UBE2S is associated with malignant characteristics of breast cancer cells", Tumour Biol, 37, pp.763~772 (2016)
- Jung CR, "E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis", Nat Med, 12, pp.809~816 (2006)
- Li Z, "Ube2s stabilizes beta-Catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development", Cell Death Dis, 9, pp.456~ (2018)
- Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
- Rosell R, "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13, pp.239~246 (2012)
- Zhou C, "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study", Lancet Oncol, 12, pp.735~742 (2011)
- Mitsudomi T, "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial", Lancet Oncol, 11, pp.121~128 (2010)
- Sequist LV, "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations", J Clin Oncol, 31, pp.3327~3334 (2013)
- Wu YL, "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial", Lancet Oncol, 15, pp.213~222 (2014)
- Solomon BJ, "First-line crizotinib versus chemotherapy in ALK-positive lung cancer", N Engl J Med, 371, pp.2167~2177 (2014)
- Dimova NV, "APC", C-mediated multiple monoubiquitylation provides an alternative degradation signal for cyclin B1, 2012, pp.14, 168~176
- Kirkpatrick DS, "Quantitative analysis of in vitro ubiquitinated cyclin B1reveals complex chain topology", Nat Cell Biol, 8, pp.700~710 (2006)
- Peters JM, "The anaphase-promoting complex:proteolysis in mitosis and beyond", Mol Cell, 9, pp.931~943 (2002)
- Ben-Eliezer I, "Appropriate expression of Ube2C and Ube2S controls the progression of the first meiotic division", FASEB J, 29, pp.4670~4681 (2015)
- Pan YH, "UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma", Biochem Biophys Res Commun, 503, pp.895~902 (2018)
- Lin TH, "Dietary flavonoids, luteolin and quercetin, inhibit invasion of cervical cancer by reduction of UBE2S through epithelial-mesenchymal transition signaling", Food Funct, 8, pp.1558~1568 (2017)
- Yoshimura S, "UBE2S associated with OSCC proliferation by promotion of P21 degradation via the ubiquitin-proteasome system", Biochem Biophys Res Commun, 485, pp.820~825 (2017)
- Yang Y, "Silencing of karyopherin alpha2 inhibits cell growth and survival in human hepatocellular carcinoma", Oncotarget, 8, pp.36289~36304 (2017)